Alkermes plc, trading on the NASDAQ under the symbol ALKS, is a biopharmaceutical company that focuses on developing innovative medicines for central nervous system disorders and cancer. The company operates within the Zacks Medical - Biomedical and Genetics industry. Alkermes has a market capitalization of approximately $5.13 billion, reflecting its significant presence in the pharmaceutical sector.
On February 26, 2026, Douglas Tsao from H.C. Wainwright set a price target of $43 for Alkermes plc (NASDAQ:ALKS). At that time, the stock was trading at $31.04, suggesting a potential upside of 38.53%. This optimistic outlook comes despite Alkermes reporting a revenue decline of 10.6% for the fourth quarter ending December 2025, with revenue at $384.55 million compared to the previous year.
Despite the revenue decline, Alkermes exceeded the Zacks Consensus Estimate of $379.96 million, resulting in a positive surprise of 1.21%. This indicates that while the company faced challenges, it still managed to outperform expectations. Such performance is crucial for investors as it provides insights into the company's ability to navigate market conditions.
Alkermes reported earnings per share (EPS) of $0.46 for the quarter, surpassing the consensus estimate of $0.43. This marks a 7.8% positive surprise, although it is a decrease from the $1.04 EPS reported in the same quarter last year. The company has consistently exceeded consensus EPS estimates in three of the last four quarters, showcasing its resilience.
The stock price of ALKS is currently $31.04, reflecting a decrease of 7.04% or $2.35. During the trading day, the stock fluctuated between $30.54 and $32.78. Over the past year, ALKS reached a high of $36.32 and a low of $25.17. The trading volume for ALKS is 3,898,927 shares, indicating active investor interest.
